Q1 2025 Holdings
Filed 2025-05-15 | 63 holdings | $1.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $156.6M | 2,387,720 | 11.2% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $104.1M | 2,590,531 | 7.4% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $82.0M | 1,075,000 | 5.9% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $76.2M | 1,075,000 | 5.4% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $60.1M | 2,500,000 | 4.3% |
| KalVista Pharmaceuticals Inc(KALV) | COM | 483497103 | $54.8M | 4,751,292 | 3.9% |
| uniQure NV(QURE) | SHS | N90064101 | $50.8M | 4,792,572 | 3.6% |
| Crinetics Pharmaceuticals Inc(CRNX) | COM | 22663K107 | $50.3M | 1,500,000 | 3.6% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $43.6M | 1,300,000 | 3.1% |
| Scholar Rock Holding Corp(SRRK) | COM | 80706P103 | $41.8M | 1,300,000 | 3.0% |
| Bicara Therapeutics Inc(BCAX) | COM | 055477103 | $36.1M | 2,768,975 | 2.6% |
| Geron Corp(GERN) | COM | 374163103 | $35.0M | 22,005,340 | 2.5% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $34.9M | 4,275,000 | 2.5% |
| Immatics NV(IMTX) | SHS | N44445109 | $32.4M | 7,192,700 | 2.3% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $31.0M | 1,788,990 | 2.2% |
| Dianthus Therapeutics Inc(DNTH) | COM | 252828108 | $30.8M | 1,700,069 | 2.2% |
| Savara Inc(SVRA) | COM | 805111101 | $30.5M | 11,000,000 | 2.2% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $26.8M | 2,879,829 | 1.9% |
| Danaher Corporation(DHR) | COM | 235851102 | $25.6M | 125,000 | 1.8% |
| UroGen Pharma Ltd(URGN) | COM | M96088105 | $23.8M | 2,152,957 | 1.7% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $23.4M | 150,142 | 1.7% |
| Astria Therapeutics Inc(CATBUSD) | COM | 04635X102 | $22.3M | 4,180,000 | 1.6% |
| Day One Biopharmaceuticals Inc(DAWN) | COM | 23954D109 | $20.6M | 2,598,127 | 1.5% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $18.8M | 1,800,000 | 1.3% |
| Ultragenyx Pharmaceutical Inc(RARE) | COM | 90400D108 | $18.1M | 500,000 | 1.3% |
| Liquidia Corp(LQDA) | COM NEW | 53635D202 | $18.1M | 1,227,403 | 1.3% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $18.0M | 3,000,000 | 1.3% |
| Establishment Labs Holdings In(ESTA) | COM | G31249108 | $17.7M | 433,193 | 1.3% |
| Verona Pharma PLC(VRNA) | SPONSORED ADS | 925050106 | $17.0M | 267,627 | 1.2% |
| Perrigo Co PLC(PRGO) | SHS | G97822103 | $16.5M | 587,649 | 1.2% |
| GE HealthCare Technologies Inc(GEHC) | COMMON STOCK | 36266G107 | $16.5M | 204,130 | 1.2% |
| Nyxoah SA(NYXH) | SHS | B6S7WD106 | $16.2M | 2,318,954 | 1.2% |
| Globus Medical Inc(GMED) | CL A | 379577208 | $14.6M | 200,000 | 1.0% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $13.4M | 1,125,552 | 1.0% |
| Sarepta Therapeutics Inc(SRPT) | COM | 803607100 | $12.8M | 200,000 | 0.9% |
| Bruker Corp(BRKR) | COM | 116794108 | $12.5M | 300,000 | 0.9% |
| Cidara Therapeutics Inc(CDTX) | COM NEW | 171757206 | $10.9M | 504,542 | 0.8% |
| Black Diamond Therapeutics Inc(BDTX) | COM | 09203E105 | $8.7M | 5,600,000 | 0.6% |
| MoonLake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $7.8M | 200,000 | 0.6% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $6.5M | 1,753,558 | 0.5% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $6.0M | 350,000 | 0.4% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $6.0M | 500,000 | 0.4% |
| Applied Therapeutics Inc(APLT) | COM | 03828A101 | $5.6M | 11,500,000 | 0.4% |
| iTeos Therapeutics Inc(5E7) | COM | 46565G104 | $5.4M | 900,000 | 0.4% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $5.0M | 200,000 | 0.4% |
| Voyager Therapeutics Inc(VYGR) | COM | 92915B106 | $4.2M | 1,249,418 | 0.3% |
| Lexeo Therapeutics Inc(LXEO) | COM | 52886X107 | $3.9M | 1,136,249 | 0.3% |
| Kiniksa Pharmaceuticals Intl(KNSA) | ORD SHS CL A | G52694109 | $3.8M | 169,864 | 0.3% |
| Celldex Therapeutics Inc(CLDX) | COM NEW | 15117B202 | $3.6M | 198,646 | 0.3% |
| OnKure Therapeutics Inc(OKUR) | COM CL A | 68277Q105 | $2.7M | 635,000 | 0.2% |